Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NRXS
SELLNeurAxis, Inc. · Healthcare · United States · $84M · Avg Vol: $515K/d
33
StockRankGet insider-trade alerts
Q
33
V
22
M
69
P/E (TTM)
—
ROE
-242.5%
D/E
0.1x
Dividend %
—
Loading 1Y...
PRICE (1Y)+0.6%
SMA 50SMA 200
Close
$6.74
RSI (14)
40.2
52W High
$9.33
From 52W High
0.7%
SCORE BREAKDOWN
Quality
33
ROIC
-198.9%2.4
ROE
-242.5%3.2
GP/Assets
56.8%91.2
Op. Margin
-108.3%17.0
FCF/Assets
-102.5%1.5
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.06x69.4
Current Ratio
2.89x52.4
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-10.8x25.0
P/FCF
—N/A
P/B
13.5x8.4
P/S
19.7x17.4
Div Yield
—N/A
Momentum
69
52W High %
72%57.8
RS 6M
31%89.8
SMA 50/200
1.30x93.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+93%71.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$84M
P/E (Forward)
-113.3x
Gross Margin
85.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NRXS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NRXS | NeurAxis, Inc.(you) | $84M | 33 | SELL |
| RLYB | Rallybio Corporation | $87M | 34 | SELL |
| SEER | Seer, Inc. | $108M | 34 | SELL |
| LONA | LeonaBio, Inc. | $69M | 30 | SELL |
| ATRA | Atara Biotherapeutics, Inc. | $71M | 29 | SELL |
| XBIT | XBiotech Inc. | $69M | 29 | SELL |
| PTHS | Pelthos Therapeutics Inc. | $90M | 24 | SELL |
| CUE | Cue Biopharma, Inc. | $135M | 30 | SELL |
| PMVP | PMV Pharmaceuticals, Inc. | $66M | 25 | SELL |
| XLO | Xilio Therapeutics, Inc. | $57M | 38 | HOLD |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%